Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. (25th May 2018)

• Record Type: Journal Article
• Authors: Neilan, Tomas G.; Rothenberg, Mace L.; Amiri‐Kordestani, Laleh; Sullivan, Ryan J.; Steingart, Richard M.; Gregory, William; Hariharan, Subramanian; Hammad, Tarek A.; Lindenfeld, JoAnn; Murphy, Martin J.; Moslehi, Javid J.
• Other Names: Abdullah Hesham investigator.; Amiri‐Kordestani Laleh investigator.; Bakker Cecilia investigator.; Boshoff Chris investigator.; Bringhurst Charlie investigator.; Bucktrout Samantha investigator.; Carlin Kathleen investigator.; Caubel Patrick investigator.; Chen Roland investigator.; Chin Kevin investigator.; Chudnovsky Aleksander investigator.; Davis John investigator.; Deutsch Jonathan investigator.; Dixit Rakesh investigator.; Gottfridsson Christer investigator.; Gregory William investigator.; Hammad Tarek A. investigator.; Handelsman Dave investigator.; Hariharan Subramanian investigator.; Holmes William investigator.; Honig Peter investigator.; Hugh‐Jones Charles investigator.; Kaufman Howard investigator.; Khan Nasir investigator.; Kozono David investigator.; Kwan Antonia investigator.; Lewis‐Hall Freda C. investigator.; Ley‐Acosta Sergio investigator.; Lindenfeld JoAnn investigator.; Michelon Elisabete investigator.; Moslehi Javid J. investigator.; Murphy Martin J. investigator.; Neilan Tomas G. investigator.; Patel Mayur investigator.; Pavlovic Dejan investigator.; Pignatti Francesco investigator.; Potter Jonathan investigator.; Reese David investigator.; Rothenberg Mace L. investigator.; Safferman Allan investigator.; Silvester Eliza investigator.; Steingart Richard M. investigator.; Sullivan Ryan J. investigator.; Zhou Ming investigator.;
• Is Part Of: Oncologist. Volume 23:Number 8(2018)
• Page Start: 874
• Page End: 878
• Publication Date: 2018-05-25
• Subjects: Immune checkpoint inhibitor -- Immune‐related adverse events -- Myocarditis -- PD‐1/PD‐L1 inhibitor -- Project Data Sphere; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2018-0157
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against normal tissue were an anticipated side effect of these agents; these immune‐related adverse events have been documented and are typically low grade and manageable. Myocarditis has emerged as an uncommon but potentially life‐threatening adverse reaction in patients treated with ICIs. Assessment and characterization of ICI‐associated myocarditis is challenging because of its low incidence and protean manifestations. Nevertheless, the seriousness of ICI‐associated myocarditis justifies a coordinated effort to increase awareness of this syndrome, identify patients who may be at risk, and enable early diagnosis and appropriate treatment. The "Checkpoint Inhibitor Safety Working Group, " a multidisciplinary committee of academic, industry, and regulatory partners, convened at a workshop hosted by Project Data Sphere, LLC, on December 15, 2017. This meeting aimed to evaluate the current information on ICI‐associated myocarditis, determine methods to collect and share data on this adverse reaction, and establish task forces to close the identified knowledge gaps. In this report, we summarize the workshop findings and proposed steps to address the impact of ICI‐associated myocarditis in patients with cancer. Abstract : Immune checkpoint inhibitors are a class of drugs that trigger the immune system to recognize and fight cancer cells; however, related immune‐related adverse events are a challenge. This commentary describes a workshop convened by Project Data Sphere to determine best approaches in the treatment of myocarditis, with the goal of minimizing the risk of this adverse reaction in patients with cancer who are treated with immune checkpoint inhibitors.